Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The 1Q earnings call hosted by Allergan plc Ordinary Shares (NYSE: AGN) gave a lot of confidence in the company’s underlying business, Goldman Sachs’ Jami Rubin said in a report. The analyst maintained a Buy rating for Allergan, with a price target of $275. He added the stock to the Americas Conviction Buy List, saying that there were “key catalysts on the horizon.”
Related Link: Berenberg Unimpressed With Pfizer, Initiates Coverage At Hold
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The price target reflects 27 percent upside, versus the 14 percent average for the large cap pharma group. Analyst Jami Rubin mentioned that the increased confidence Allergan was based on:
- A “sharpened” business model that was focused on branded growth pharma
- A reloaded balance sheet that seemed poised to de-lever from 4X to 1.5X following the deal with Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)
- Clear signal of management confidence reflecting in the $10bn share repo authorization
- Expectation of double-digit topline growth, based on volume-driven durable assets including differentiated new products
- Rich pipeline with about 70 unique assets including a number of “first-in-class and/or best-in-class candidates
“We believe AGN is on track to deliver sustainable topline growth with operating margin expansion,” Rubin wrote.
Two Important Catalysts
Rubin mentioned two catalysts that would unlock significant shareholder value in the next few months:
- “First, we believe investor concern around closing the TEVA deal can be mitigated by progress being made with the FTC review, which is complete for marketed drugs and nearly complete for the pipelines including remedies,” the analyst stated.
- Management could close the $4-$5bn of share repos pending deal and execute another $4-$5bn based on the $10bn authorized.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.